XML 26 R15.htm IDEA: XBRL DOCUMENT
v3.25.2

Grant Income | 6 Months Ended
--- | ---
Jun. 30, 2025
Grant Income |
Grant Income | (7)Grant Income In September 2024, the Company received its second Award (the “2024 Award”) from the National Cancer Institute of the National Institutes of Health (the “NIH”). The 2024 Award is a Direct to Phase II SBIR Award to support IND-enabling and clinical trial activities in the Company’s clinical trial with its lead candidate, TTX-MC138, over two years. The total 2024 Award is for $1,999,972 of which $1,011,207 applies to the first year and $988,765 applies to the second year. The Company recognized grant income of $153,685 and $0 for the three months ended June 30, 2025 and 2024, respectively, and $501,529 and $27,057, respectively, for the six months ended June 30, 2025, and 2024. The Company had deferred grant income of $0 at June 30, 2025, and $25,408 at December 31, 2024, respectively.

X
- References No definition available. + Details
Name: | rnaz_DeferredGrantIncomeAbstract
Namespace Prefix: | rnaz_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of deferred grant income. + References No definition available. + Details
Name: | rnaz_DeferredGrantIncomeDisclosureTextBlock
Namespace Prefix: | rnaz_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration